CRDF Cardiff Oncology Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CRDF

Price (delayed)

$1.57

Market cap

$107.34M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.67

Enterprise value

$99.44M

?
Relative Growth: Rel. Growth: 29
Relative Strength: Rel. Strength: 7
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 30

Cardiff Oncology is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need. Its goal is to ...

Highlights
Cardiff Oncology's debt has shrunk by 52% YoY and by 22% QoQ
Cardiff Oncology's EPS has increased by 27% YoY and by 2.9% QoQ
The equity has dropped by 51% year-on-year and by 24% since the previous quarter
The quick ratio has contracted by 47% YoY and by 10% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://cardiffoncology.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of CRDF

CRDF stock price

How has the Cardiff Oncology stock price performed over time
Intraday
12.14%
1 week
-14.67%
1 month
-4.85%
1 year
-56.63%
YTD
-44.13%
QTD
-3.09%

Financial performance

How have Cardiff Oncology's revenue and profit performed over time
Revenue
$525,000
Gross profit
$525,000
Operating income
-$47.43M
Net income
-$44.76M
Gross margin
100%
Net margin
-8,526.1%
The gross profit has decreased by 11% QoQ and by 11% YoY
Cardiff Oncology's revenue has decreased by 11% from the previous quarter and by 11% YoY
Cardiff Oncology's net margin has decreased by 10% QoQ and by 2.6% YoY
The operating margin has declined by 9% since the previous quarter

Price vs fundamentals

How does CRDF's price correlate with its fundamentals

Growth

What is Cardiff Oncology's growth rate over time

Valuation

What is Cardiff Oncology stock price valuation
P/E
N/A
P/B
3.09
P/S
204.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
189.41
Cardiff Oncology's EPS has increased by 27% YoY and by 2.9% QoQ
The equity has dropped by 51% year-on-year and by 24% since the previous quarter
The stock's price to book (P/B) is 38% more than its 5-year quarterly average of 2.0 but 19% less than its last 4 quarters average of 3.4
The P/S is 40% less than the 5-year quarterly average of 306.3 and 39% less than the last 4 quarters average of 296.6
Cardiff Oncology's revenue has decreased by 11% from the previous quarter and by 11% YoY

Efficiency

How efficient is Cardiff Oncology business performance
Cardiff Oncology's return on equity has decreased by 25% YoY and by 16% QoQ
CRDF's return on assets is down by 14% year-on-year and by 12% since the previous quarter
The company's return on invested capital fell by 12% QoQ but it rose by 4.3% YoY
Cardiff Oncology's return on sales has decreased by 10% QoQ and by 2.6% YoY

Dividends

What is CRDF's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRDF.

Financial health

How did Cardiff Oncology financials performed over time
The company's current ratio fell by 47% YoY and by 11% QoQ
The quick ratio has contracted by 47% YoY and by 10% from the previous quarter
Cardiff Oncology's debt is 98% lower than its equity
Cardiff Oncology's debt has shrunk by 52% YoY and by 22% QoQ
The equity has dropped by 51% year-on-year and by 24% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.